| Related Articles |
Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.
Nat Rev Clin Oncol. 2018 Apr 27;:
Authors: Killock D
PMID: 29703915 [PubMed - as supplied by publisher]
from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader https://ift.tt/2jhGrDx
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου